| Oct 7 |
Immutep: Navigating The Bumps In The Road
|
| Oct 4 |
Immutep concludes participant enrolment in Phase II breast cancer trial
|
| Oct 3 |
Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer
|
| Sep 24 |
Immutep receives A$3.6M R&D tax incentive from French government
|
| Sep 24 |
Immutep Receives A$3.6 million R&D Tax Incentive from French Government
|
| Sep 18 |
New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma
|
| Sep 16 |
Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
|
| Aug 20 |
Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024
|
| Aug 14 |
Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody
|
| Aug 8 |
Both retail investors who control a good portion of Immutep Limited (ASX:IMM) along with institutions must be dismayed after last week's 10% decrease
|
